BRPI0411949A - formulação inalável de lisinato de aztreonam para tratamento e prevenção de infecções pulmonares bacterianas - Google Patents

formulação inalável de lisinato de aztreonam para tratamento e prevenção de infecções pulmonares bacterianas

Info

Publication number
BRPI0411949A
BRPI0411949A BRPI0411949-5A BRPI0411949A BRPI0411949A BR PI0411949 A BRPI0411949 A BR PI0411949A BR PI0411949 A BRPI0411949 A BR PI0411949A BR PI0411949 A BRPI0411949 A BR PI0411949A
Authority
BR
Brazil
Prior art keywords
aztreonam lysinate
treatment
prevention
formulation
bacterial
Prior art date
Application number
BRPI0411949-5A
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Manfred Keller
Frank Christophe Lintz
Original Assignee
Corus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34083679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/613,639 external-priority patent/US7214364B2/en
Application filed by Corus Pharma Inc filed Critical Corus Pharma Inc
Publication of BRPI0411949A publication Critical patent/BRPI0411949A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO INALáVEL DE LISINATO DE AZTREONAM PARA TRATAMENTO E PREVENçãO DE INFECçõES PULMONARES BACTERIANAS". Descreve-se um método e uma composição para tratamento de infecções bacterianas pulmonares causadas por bactérias gram-negativas, satisfatórios para o tratamento de infecções causadas por Escherichia Coli, Klebaiella Pneumoniae, Klebsíella Oxytoca, Pseudomonas Aeruginosa, Haemophilus Influenzae, Probeus Mirabilis, espécies de Enterobactérias, Serratia Marcescens bem como aquelas causadas por Burkholderia Cepacia, Stenotrophomonas Malbophilia, Alcaligenes Xylosoxidans, e Pseudomonas Aeruginosa resistente a multi-drogas, usando uma formulação concentrada de lisinato de aztreonam distribuida como um aerossol ou uma formulação de pó seco. Descreve-se também um processo de fabricação para lisinato de aztreonam.
BRPI0411949-5A 2003-07-03 2004-07-01 formulação inalável de lisinato de aztreonam para tratamento e prevenção de infecções pulmonares bacterianas BRPI0411949A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/613,639 US7214364B2 (en) 2000-12-27 2003-07-03 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US10/882,985 US7138419B2 (en) 2000-12-27 2004-06-30 Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
PCT/US2004/021517 WO2005007132A1 (en) 2003-07-03 2004-07-01 Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Publications (1)

Publication Number Publication Date
BRPI0411949A true BRPI0411949A (pt) 2006-08-29

Family

ID=34083679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411949-5A BRPI0411949A (pt) 2003-07-03 2004-07-01 formulação inalável de lisinato de aztreonam para tratamento e prevenção de infecções pulmonares bacterianas

Country Status (13)

Country Link
US (1) US7138419B2 (pt)
EP (3) EP1641436B2 (pt)
JP (1) JP2007527398A (pt)
BR (1) BRPI0411949A (pt)
CA (1) CA2530774C (pt)
CY (2) CY1114621T1 (pt)
DK (2) DK1641436T4 (pt)
ES (2) ES2655036T3 (pt)
HU (2) HUE035150T2 (pt)
PL (2) PL1641436T5 (pt)
PT (2) PT1641436E (pt)
SI (2) SI2158901T1 (pt)
WO (1) WO2005007132A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
ES2351651B2 (es) * 2003-07-02 2011-09-28 Gilead Sciences Inc. Método para la determinación de impurezas en una sal de lisina de aztreonám amorfa.
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2200608A1 (en) * 2007-10-01 2010-06-30 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
EP3443970B1 (en) * 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
RU2015138796A (ru) * 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
CN107805618B (zh) * 2017-12-03 2021-04-06 李峰 一种改造盐碱地耕种性的微生物菌剂及其制备方法
CN110857474B (zh) * 2018-08-24 2023-04-18 武汉远大弘元股份有限公司 L-半胱氨酸盐酸盐一水合物的处理方法
WO2020174365A1 (en) * 2019-02-28 2020-09-03 Exorao Life Science S.R.L. Sterile aztreonam package
EP3991750A4 (en) * 2019-06-26 2022-08-03 Ricoh Company, Ltd. PHARMACEUTICAL COMPOSITION

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US3984403A (en) † 1972-06-30 1976-10-05 Takeda Chemical Industries, Ltd. Arginine and lysine salts of acid cephalosporins
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4826973A (en) 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
WO1995019180A1 (en) 1994-01-14 1995-07-20 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
MXPA02004193A (es) 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
US7138419B2 (en) † 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof

Also Published As

Publication number Publication date
HUS1800012I1 (hu) 2018-03-28
CA2530774C (en) 2011-10-18
EP1641436B1 (en) 2013-09-04
HK1089359A1 (en) 2006-12-01
ES2428030T3 (es) 2013-11-05
EP2158901B1 (en) 2017-10-18
HUE035150T2 (en) 2018-05-02
EP1641436A1 (en) 2006-04-05
CY1119753T1 (el) 2018-06-27
DK2158901T3 (en) 2018-01-15
EP2158901A2 (en) 2010-03-03
EP2452672A3 (en) 2013-11-06
PL2158901T3 (pl) 2018-05-30
PL1641436T5 (pl) 2017-10-31
PT1641436E (pt) 2013-11-07
PT2158901T (pt) 2018-01-15
EP1641436B2 (en) 2017-05-10
WO2005007132A1 (en) 2005-01-27
EP2452672A2 (en) 2012-05-16
DK1641436T3 (da) 2013-09-30
CY1114621T1 (el) 2016-10-05
ES2428030T5 (es) 2017-07-25
CA2530774A1 (en) 2005-01-27
US20050063912A1 (en) 2005-03-24
JP2007527398A (ja) 2007-09-27
SI1641436T1 (sl) 2013-12-31
DK1641436T4 (en) 2017-07-17
PL1641436T3 (pl) 2014-02-28
SI2158901T1 (en) 2018-02-28
US7138419B2 (en) 2006-11-21
SI1641436T2 (sl) 2017-08-31
ES2655036T3 (es) 2018-02-16
EP2158901A3 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
BR0116757A (pt) Método para o tratamento de infecções pulmonares causadas por bactérias gram-negativas e composição para inalação farmaceuticalmente aceitável.
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
PT1273292E (pt) Formulacao optimizada de tobramicina para aerossolizacao
BRPI0411713A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BR0206935A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
WO2003097574A3 (en) Aminoalkoxy-functional chalcones
WO2004096802A3 (en) ANTIBIOTIC TETRAHYDRO-β-CARBOLINE DERIVATIVES
WO2018232453A1 (en) Method for reducing lung infection
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
Tektook The antibacterial effect of extracts of Salvadora perscia against oral pathogenic bacteria isolated from dental caries
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
WO2006125123A3 (en) Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
Sabnis Novel Tricyclic Compounds for Treating Bacterial Infections
Subramanian Molecular Characterization of Cariogenic, Biofilm-forming, Multi-drug-resistant Pseudomonas aeruginosa and Detection of NDM-1 and blaVIM-1 Genes
AU2003208510A8 (en) Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma(obstructive lung disease)
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
NO20042660L (no) Fremgangsmate til a behandle bakterielle infeksjoner ved a bruke gemifloksasin eller et salt derav og karbapenem antibakterielt middel
BR0313228A (pt) Derivados de poliisoprenila - benzofenona, processo para sua preparação, e emprego dos mesmos

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A TRANSFERENCIA SOLICITADA NA PETICAO NO 018090015540/SP DE 27/03/2009, UMA VEZ QUE O TITULAR DO PROCESSO JA ESTA NO NOME DO CESSIONARIO DA PRIMEIRA TRANSFERENCIA REQUERIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: GILEAD SCIENCES, INC. (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: CORUS PHARMA, INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]